Related references
Note: Only part of the references are listed.Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer
Franco Muggia
GYNECOLOGIC ONCOLOGY (2009)
被撤回的出版物: Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (Retracted article. See vol. 28, pg. 5229, 2010)
David S. Hsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of resistance to cisplatin and carboplatin
David J. Stewart
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines
Xue-dong Yan et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells
Laura Martelli et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
M Komatsu et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas
E Yakirevich et al.
GYNECOLOGIC ONCOLOGY (2006)
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives
D Lorusso et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients
P Surowiak et al.
VIRCHOWS ARCHIV (2005)
Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide
H Mizutani et al.
LIFE SCIENCES (2005)
The comet assay for DNA damage and repair - Principles, applications, and limitations
AR Collins
MOLECULAR BIOTECHNOLOGY (2004)
Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia
BM Frost et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
S Sharma et al.
BMC CANCER (2003)
Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma:: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP
K Nakayama et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors
T Satoh et al.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2001)
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients
A von Heideman et al.
ANNALS OF ONCOLOGY (2000)
Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas
D Mayr et al.
PATHOLOGY RESEARCH AND PRACTICE (2000)
Share Paper
